Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Overview
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Companies Involved in Therapeutics Development
Biogen Inc
Bristol-Myers Squibb Co
ChemoCentryx Inc
Generium
GlaxoSmithKline Plc
Humanigen Inc
iBio Inc
InflaRx NV
Insmed Inc
Nichi-Iko Pharmaceutical Co Ltd
Pharmapraxis
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HGEN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INS-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Dormant Projects
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Discontinued Products
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Product Development Milestones
Featured News & Press Releases
Jan 30, 2020: The CHMP recommended extensions of indication for MabThera
Oct 09, 2019: Two new options for self-administration of NUCALA now approved in Cada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment
Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication
Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders
May 16, 2019: GSK presents Nucala at ATS 2019
Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Dec 12, 2017: GSK Achieves Approval for Nucala (mepolizumab) for the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) for Adults in the US
Jun 28, 2017: GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Desigtion for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Mar 25, 2014: NICE says yes to new treatment for rare autoimmune disease in fil guidance
Feb 14, 2014: GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera
Apr 19, 2011: Genentech Receives FDA Approval For Rituxan Plus Steroid For Use In Severe Forms Of Vasculitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Biogen Inc, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Bristol-Myers Squibb Co, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by ChemoCentryx Inc, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Generium, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by GlaxoSmithKline Plc, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Humanigen Inc, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by iBio Inc, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by InflaRx NV, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Insmed Inc, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Pipeline by Pharmapraxis, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Dormant Projects, H1 2020
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - Discontinued Products, H1 2020